CClinicalTrials.gg
CompletedNCT00040326ERSETUpdated Feb 23, 2010

Early Surgical Intervention to Treat Epilepsy

A Phase 3 interventional study of anteromesial temporal resection and antiepileptic drugs in Epilepsy, Epilepsy, Temporal Lobe and Seizures, sponsored by University of California, Los Angeles. Completed at 12 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2010-02-23.

Sponsored by University of California, Los Angeles · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this trial is to compare the effectiveness of early surgical intervention for mesial temporal lobe epilepsy to continued treatment with antiepileptic drugs.

Read the detailed description

Mesial temporal lobe epilepsy (MTLE) is the most common form of epilepsy, and the most medically intractable. An estimated one-quarter to one-half of the 400,000 patients in the United States with intractable epilepsy have MTLE. Generally, MTLE becomes intractable in adolescence and early adulthood. Persistence of seizures during this time commonly causes adverse social and psychological consequences which can become irreversible.

The current treatment of MTLE primarily consists of medications to control seizures. Usually surgical treatment is considered only if medications are not effective. Recent studies have shown that surgery can stop disabling seizures in 60 to 70% of patients with long standing MTLE. However, to date, no research study has examined surgery performed as an early therapy.

The goal of the study is to determine if more patients treated with early surgery become seizure free and have improved quality of life compared to similar patients who continue to receive antiepileptic medication only. This study will determine the difference in seizure frequency between the two groups and the impact of the two treatments on the quality of life of the participants.

02

Conditions studied

  • Epilepsy
  • Epilepsy, Temporal Lobe
  • Seizures

Keywords

  • epilepsy
  • mesial temporal lobe epilepsy
  • temporal lobe epilepsy
  • MTLE
  • seizures
  • anteromesial temporal resection
  • surgery
  • antiepileptic drugs
  • hippocampal sclerosis
03

In context

Epilepsy

1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.

This study's planned enrollment of 200 is above the median of 50 across 1,206 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Intractability: Two AEDs, one of which was either Dilantin, Tegretol, Carbatrol, or Trileptal used in appropriate doses, have failed due to inefficacy, not intolerance.
  • Frequency and Duration: Persistence of disabling seizures at 6 per year or greater for less than two years after onset, or after recurrence if initial treatment resulted in seizure freedom for 6 or more months.
  • Age: 12 years or older at baseline visit.
  • History: Simple and complex partial seizures, with or without secondarily generalized seizures beginning in childhood or later, with or without febrile convulsions earlier.
  • Absence of a history of serious cerebral insult after the age of 5; a progressive neurological disorder; mental retardation (I.Q. less than 70); psychogenic seizures; focal neurological deficits other than memory disturbances; unequivocal focal extratemporal EEG slowing or interictal spikes; or lesions on neuroimaging outside of the mesial temporal area.
  • Seizure semiology: Auras that occur in isolation and are not primary sensory other than olfactory or gustatory. Absence of initial focal motor movements other than automatisms or dystonic posturing. Presence of postictal confusion.
  • Neurological examination: No unexplained focal or lateralized neurological deficits other than memory dysfunction.
  • Baseline QOL and ancillary outcome data:
  • Adolescents - QOLIE-48-AD, CHQ, CBCL, PANAS, Life Events Scale, FAC, FEICS-PC completed.
  • Adults - QOLIE-82/ESI55, locus of control, PANAS, Life Events Scale, FAD, FEICS-PC completed.
  • Global rating scale completed.
  • Baseline ancillary outcomes completed. Psychiatric evaluation: No evidence of psychosis, current or recent substance abuse, suicidality, anorexia, or psychogenic seizures. Baseline BSI and MINI or KSADS completed.
  • Neuropsychological testing: I.Q. of greater than 70. No significant focal neurocognitive dysfunction inconsistent with MRI and PET findings. Baseline neuropsychological testing completed.
  • Neuroimaging: Hippocampal atrophy on MRI T1 imaging with either increased ipsilateral mesial signal on T2 imaging, or ipsilateral hypometabolism on PET (Class I), or either hippocampal atrophy on MRI only, or temporal hypometabolism on PET only (Class II).
  • Absence of temporal neocortical or extratemporal lesions on MRI, or diffuse unilateral or bilateral hypometabolism on PET.
  • Video-EEG Monitoring:
  • If neuroimaging is Class I, ictal EEG onset is lateralized to the ipsilateral side; if neuroimaging is Class II, ictal EEG onset is focal on the ipsilateral side.
  • Absence of contralateral or extratemporal ictal onset.
  • Absence of persistent extratemporal, or predominant contralateral focal interictal spikes or slowing, or generalized interictal spikes.
  • Absence of psychogenic seizures.
  • Seizure baseline: Seizure log, seizure report forms, and seizure severity scale completed.
  • IAP: In those randomized to surgery only, contralateral hemisphere can support memory.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    1

    anteromesial temporal resection

    Procedure: anteromesial temporal resection

  • Active comparator
    2

    antiepileptic drugs

    Drug: antiepileptic drugs

Interventions

  • Procedureanteromesial temporal resection

    surgical treatment for epilepsy

  • Drugantiepileptic drugs

    pharmacotherapy

06

What researchers measure

Primary outcomes

  1. The primary outcome measure will be freedom from disabling epileptic seizures (complex partial and secondarily generalized seizures, and simple partial seizures that are apparent to an observer)

    Time frame: 2 years

07

Study locations

12 sites
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • UCLA School of Medicine, Department of Neurology
    Los Angeles, California 90095-1769, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Michigan, Department of Neurology
    Ann Arbor, Michigan 48109-0036, United States
  • University of Rochester, Department of Neurology
    Rochester, New York 14642, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Vanderbilt University
    Nashville, Tennessee 37212, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
08

References and documents

Publications

  • Engel J Jr, McDermott MP, Wiebe S, Langfitt JT, Stern JM, Dewar S, Sperling MR, Gardiner I, Erba G, Fried I, Jacobs M, Vinters HV, Mintzer S, Kieburtz K; Early Randomized Surgical Epilepsy Trial (ERSET) Study Group. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012 Mar 7;307(9):922-30. doi: 10.1001/jama.2012.220. PubMed 22396514 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 23, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00040326
Lead sponsor
University of California, Los Angeles
First posted
Jun 25, 2002
Start date
Jul 2002
Primary completion
Nov 2007
Completion
Nov 2007
Last update
Feb 23, 2010

Study contacts

Jerome Engel, Jr., M.D., Ph.D.
principal investigator · UCLA School of Medicine, Department of Neurology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion